ReviewBiomolecules2024
The Role of Gut Microbiome in Irritable Bowel Syndrome: Implications for Clinical Therapeutics.
Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A bibliometric analysis of global research status and trends in irritable bowel syndrome and gut microbiota metabolites.Frontiers in microbiology · 2025Pooled it
- The immunoproteasome in Alzheimer's disease: a dual regulator of tau pathology and microglial senescence.Inflammopharmacology · 2026Review
- Identification and Validation of Candidate Biomarkers Co-expressed with Creatine Metabolism-Related Genes in Ischemic Stroke Based on Transcriptomics Data.Molecular neurobiology · 2026Article
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pathophysiology-driven use of natural products in irritable bowel syndrome: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Is MASLD Not Just a Liver Disease? Bidirectional Gut-Liver Crosstalk as a Driver of Chronic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Widespread adhesion and iron acquisition traits in Escherichia coli strains obtained from irritable bowel syndrome (IBS) patients.BMC research notes · 2026Article
- Targeting Reactive Astrocytes with Flavonoids to Alleviate Neuroinflammation and Promote Synaptic Function.Molecular neurobiology · 2026Review
- Application of neuromodulation techniques in irritable bowel syndrome.Frontiers in neuroscience · 2026Review
- Clinical efficacy and gastrointestinal hormonal effect ofAmerican journal of translational research · 2026Article
- HIF-1α inhibits the TLR4/NF-κB signaling pathway and modulates intestinal flora in diarrhea-predominant irritable bowel syndrome.PloS one · 2026Article
- Effect of autophagy-related (Atg) protein 5 on mouse epididymal sperm maturation.Journal of assisted reproduction and genetics · 2026Article
- Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
- Unraveling the Association Between Fibromyalgia and Irritable Bowel Syndrome: A Systematic Review.Cureus · 2025Review
- Impact of Diet on Gut Microbiota in Diverticular Disease of the Colon: An Exploratory Retrospective Study.Microorganisms · 2025Article
- Resistant Starch and Microbiota-Derived Secondary Metabolites: A Focus on Postbiotic Pathways in Gut Health and Irritable Bowel Syndrome.International journal of molecular sciences · 2025Review
- Elevated Plasma m6A Demethylase FTO Levels Predict Favorable Outcomes Following Acute Ischemic Stroke.Cellular and molecular neurobiology · 2025Article
- Antibiotic Cocktail Exacerbates Esomeprazole-Induced Intestinal Dysmotility While Ameliorating Gastric Dyspepsia in Mice.Antibiotics (Basel, Switzerland) · 2025Article
- Microbiota-oriented strategies to mitigate parenteral nutrition-related complications in intestinal failure: A narrative review.Intestinal Failure (New York, N.Y.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) characterized by chronic or recurrent gastrointestinal symptoms without organic changes, and it is also a common disorder of gut-brain interaction (DGBIs).. The symptoms of IBS not only affect the quality of life for individual patients but also place a significant burden on global healthcare systems. The lack of established and universally applicable biomarkers for IBS, along with the substantial variability in symptoms and progression, presents challenges in developing effective clinical treatments. In recent years, preclinical and clinical studies have linked the pathogenesis of IBS to alterations in the composition and function of the intestinal microbiota. Within the complex microbial community of the gut, intricate metabolic and spatial interactions occur among its members and between microbes and their hosts. Amid the multifaceted pathophysiology of IBS, the role of intestinal microenvironment factors in symptom development has become more apparent. This review aims to delve into the changes in the composition and structure of the gut microbiome in individuals with IBS. It explores how diet-mediated alterations in intestinal microbes and their byproducts play a role in regulating the pathogenesis of IBS by influencing the "brain-gut" axis, intestinal barrier function, immune responses, and more. By doing so, this review seeks to lay a theoretical foundation for advancing the development of clinical therapeutics for IBS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.